(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
UN chief calls on Yemen's Houthi rebels to free all UN detainees - 2Instructions to Explore the Universe of Vehicle Leases
- 3Consumer outlook on UK economy falls to two-year low
- 4American Airlines Flight Attendant Disappears Amid Layover in Colombia, Authorities Investigating
- 5The most effective method to Make a Dazzling Site in 5 Basic Advances
- Finding the Universe of Computer generated Reality: Individual Encounters
- Israeli Chief of Staff declares new border with Gaza Strip
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
- Wedding trip Objections in the US
- German police 'cleared path for fascists with batons,' protesters say
- The secret appeal of Harlan Coben’s messy, addictive TV thrillers
- The Drone Video of the Year is stunning – you've not seen Namibia like this
